F S&P 500
5,354.00 +26.00 (+0.49%) F Dow Jones
39,800.00 +17.00 (+0.04%) F Nasdaq
18,944.25 +157.50 (+0.84%) E-mini Russell 2000 Index Futur
2,093.20 +4.10 (+0.20%) Petróleo
77.84 +0.27 (+0.35%) Oro
2,365.20 -27.70 (-1.16%)
Shanghai Bio-heart Biological Technology Co., Ltd. (2185.HK)
Shanghai Bio-heart Biological Technology Co., Ltd.
Building 4
Room 302, 3rd Floor No.590 Ruiqing Road E. Zhangjiang Hi-Tech Park, Pudong New A
Shanghai
China
86 21 6879 8511
https://www.bio-heart.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 32
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Li Wang | Executive Chairman of the Board, CEO & GM | 777.77k | N/D | 1968 |
| Mr. Yunqing Wang | CFO, Joint Company Secretary & Executive Director | 1.29M | N/D | 1985 |
| Ms. Peili Wang | Financial Manager & Executive Director | 829.4k | N/D | 1984 |
| Dr. Bradley Stewart Hubbard D.V.M., DVM | Chief Medical Officer | N/D | N/D | 1959 |
| Ms. Siu Ying Kwok | Joint Company Secretary | N/D | N/D | 1985 |
| Mr. Tao Cai | Chairperson of the Board of Supervisors & Head of Technology of BRS | 177.96k | N/D | 1987 |
Descripción
Shanghai Bio-heart Biological Technology Co., Ltd. operates as an interventional cardiovascular device company in the People's Republic of China. The company focuses on the provision of bioresorbable scaffolds (BRS) and renal denervation (RDN) therapies for the treatment of coronary artery diseases and uncontrolled and resistant hypertension. It is developing Bioheart, a BRS system used in percutaneous coronary intervention procedures for the treatment of coronary artery disease; Iberis 2nd, a multi-electrode RDN product candidate; and drug coated balloon, a sirolimus drug-eluting balloon catheter designed for instent restenosis. The company has collaboration agreements with Terumo (China) Investment Co., Ltd. to conduct clinical trials for Iberis 2nd. Shanghai Bio-heart Biological Technology Co., Ltd. was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
Gestión corporativa
La calificación ISS Governance QuickScore de Shanghai Bio-heart Biological Technology Co., Ltd. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
